ClearLine MD, a Woburn, MA-based medical device company focused on reducing the impact of iatrogenic Air Burden to patients and improving the safety and effectiveness of intravenous (IV) therapy, closed its $5.5m funding round.
Backers included Rosse Enterprises, the family office of Tom Rosse, founder of Instrumentation Laboratory.
The company intends to use the funds for direct go-to-market initiatives and strategic partner activities.
Led by Ann Bilyew, President & CEO, ClearLine MD is developing technology offering a solution for continuously monitoring IV lines for the presence of air and then automatically removing that air. The ClearLine IV is an FDA-cleared device that continuously monitors a patient’s IV lines for the presence of air and helps clinicians manage and avoid one of the primary risks associated with IV therapy.